Nakagawa, Takahiko
Ana Andres-Hernando,
Kosugi, Tomoki
Sanchez-Lozada, Laura G.
Stenvinkel, Peter
Kublickiene, Karolina
Ananth Karumanchi, S.
Kang, Duk-Hee
Kojima, Hideto
Rodriguez-Iturbe, Bernardo
Tolan, Dean R.
Lanaspa, Miguel A.
Johnson, Richard J.
Article History
Received: 2 September 2022
Revised: 20 October 2022
Accepted: 5 November 2022
First Online: 20 December 2022
Compliance with ethical standards
:
: MAL, DRT, LGL, and RJJ have shares in a start-up company developing fructokinase inhibitors (Colorado Research Partners LLC). TN and RJJ have shares in XORTX therapeutics, which is developing novel xanthine oxidase inhibitors. Dr. Johnson is a consultant for Horizon Pharmaceuticals, Inc. Dr. Karumanchi is a coinventor on patents for the use of angiogenic biomarkers in preeclampsia, has served as consultant for Roche and Thermo Fisher Scientific and has financial interest in Aggamin Pharmaceuticals and Comanche Biopharma. All other authors declare no conflicts of interest.